Clinical Trial Update: A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye Disease [Phase 3]

View source ↗

Summary

Phase 3 safety and efficacy study of Tavilermide (MIM-D3) ophthalmic solution for dry eye disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Keratoconjunctivitis Sicca

Drugs mentioned

• Tavilermide (Tavilermide)

Snippet

Sponsor: Mimetogen Pharmaceuticals USA, Inc. | Conditions: Keratoconjunctivitis Sicca | Phase 3 | Status: COMPLETED